A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies

[1] Fenwick C(2022)Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys Nat Microbiol 7 1376-1389

[2] Turelli P(2021)A highly potent antibody effective against SARS-CoV-2 variants of concern Cell Rep 37 157-159

[3] Ni D(2010)Enhanced antibody half-life improves in vivo activity Nat Biotechnol 28 682-687

[4] Fenwick C(2021)Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants Front Immunol 12 382-393

[5] Turelli P(2020)SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Nature 588 84-1730

[6] Perez L(2021)Neutralizing monoclonal antibodies for treatment of COVID-19 Nat Rev Immunol 21 1720-338

[7] Zalevsky J(2005)Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis Virol J 2 325-99

[8] Chamberlain AK(2020)Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness United States Emerg Infect Dis 26 96-4428

[9] Horton HM(2021)The immune response to SARS-CoV-2 vaccination: insights learned from adult patients with common variable immune deficiency Front Immunol 12 4423-2040

[10] Shrestha LB(2010)The safety and side effects of monoclonal antibodies Nat Rev Drug Discov 9 2032-488.e11

[1] Fenwick C(2022)Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys Nat Microbiol 7 1376-1389

[2] Turelli P(2021)A highly potent antibody effective against SARS-CoV-2 variants of concern Cell Rep 37 157-159

[3] Ni D(2010)Enhanced antibody half-life improves in vivo activity Nat Biotechnol 28 682-687

[4] Fenwick C(2021)Broadly-neutralizing antibodies against emerging SARS-CoV-2 variants Front Immunol 12 382-393

[5] Turelli P(2020)SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Nature 588 84-1730

[6] Perez L(2021)Neutralizing monoclonal antibodies for treatment of COVID-19 Nat Rev Immunol 21 1720-338

[7] Zalevsky J(2005)Development of an improved microneutralization assay for respiratory syncytial virus by automated plaque counting using imaging analysis Virol J 2 325-99

[8] Chamberlain AK(2020)Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness United States Emerg Infect Dis 26 96-4428

[9] Horton HM(2021)The immune response to SARS-CoV-2 vaccination: insights learned from adult patients with common variable immune deficiency Front Immunol 12 4423-2040

[10] Shrestha LB(2010)The safety and side effects of monoclonal antibodies Nat Rev Drug Discov 9 2032-488.e11